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Abstract 
Background: Placental malaria (PM) has been associated with a higher risk of malaria during infancy. However, it is 
unclear whether this association is causal, and is modified by infant sex, and whether intermittent preventive treat-
ment in pregnancy (IPTp) can reduce infant malaria by preventing PM.
Methods: Data from a birth cohort of 656 infants born to HIV-uninfected mothers randomised to IPTp with dihy-
droartemisinin–piperaquine (DP) or Sulfadoxine–pyrimethamine (SP) was analysed. PM was categorized as no PM, 
active PM (presence of parasites), mild-moderate past PM (> 0–20% high powered fields [HPFs] with pigment), or 
severe past PM (> 20% HPFs with pigment). The association between PM and incidence of malaria in infants strati-
fied by infant sex was examined. Causal mediation analysis was used to test whether IPTp can impact infant malaria 
incidence via preventing PM.
Results: There were 1088 malaria episodes diagnosed among infants during 596.6 person years of follow-up. Com-
pared to infants born to mothers with no PM, the incidence of malaria was higher among infants born to mothers 
with active PM (adjusted incidence rate ratio [aIRR] 1.30, 95% CI 1.00–1.71, p = 0.05) and those born to mothers with 
severe past PM (aIRR 1.28, 95% CI 0.89–1.83, p = 0.18), but the differences were not statistically significant. However, 
when stratifying by infant sex, compared to no PM, severe past PM was associated a higher malaria incidence in male 
(aIRR 2.17, 95% CI 1.45–3.25, p < 0.001), but not female infants (aIRR 0.74, 95% CI 0.46–1.20, p = 0.22). There were no 
significant associations between active PM or mild-moderate past PM and malaria incidence in male or female infants. 
Male infants born to mothers given IPTp with DP had significantly less malaria in infancy than males born to mothers 
given SP, and 89.7% of this effect was mediated through prevention of PM.
Conclusion: PM may have more severe consequences for male infants, and interventions which reduce PM could 
mitigate these sex-specific adverse outcomes. More research is needed to better understand this sex-bias between 
PM and infant malaria risk.
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Background
Plasmodium falciparum remains a major public health 
problem affecting mainly pregnant women and young 
children. In pregnant women infected with P. falcipa-
rum, parasitized erythrocytes sequester in the placenta, 
resulting in placental malaria (PM), which is character-
ized by placental inflammation, parasite infiltration, and 
deposition of malaria pigment, a product of digestion of 
haemoglobin by P. falciparum [1]. Placental malaria is 
associated with adverse effects such as preterm delivery, 
low birth weight, stillbirth and neonatal mortality [2–4]. 
Despite the use of preventive measures, including insec-
ticide-treated nets and intermittent preventive therapy 
during pregnancy (IPTp), the burden of PM among preg-
nant women living in high malaria transmission settings 
remains high [5].
There is evidence that PM may impact infants after 
birth [6–8]. Several observational studies have reported 
associations between PM and increased risks of malaria, 
non-malaria febrile illnesses, and anaemia in infancy, 
possibly due to immune tolerance induced by in utero 
exposure to malaria antigens [9–13]. However, most 
of these studies defined PM as the detection of malaria 
parasites in placental blood by microscopy, which has 
limited sensitivity and does not account for past placen-
tal infections characterized by the presence of malaria 
pigment [14]. Furthermore, the severity of malaria pig-
ment deposition in the placenta was recently shown to 
be strongly predictive of adverse birth outcomes includ-
ing low birth weight and preterm birth [15]. Whether the 
severity of malaria pigment deposition in the placenta 
is also associated with the risk of malaria in infancy is 
unknown.
A recent double-blind randomised controlled trial 
compared the incidence of malaria during infancy among 
infants born to mothers who received monthly IPTp with 
dihydroartemisin-piperaquine (DP) versus Sulfadoxine–
pyrimethamine (SP). In this trial, infants born to moth-
ers receiving IPTp-DP had a lower malaria incidence 
compared to infants born to mothers receiving IPTp-SP. 
However, this association was observed in male, but not 
female, infants [16]. To further evaluate the association 
between PM and the incidence of malaria in infants, a 
secondary and mediation analysis of these data was car-
ried out to examine how much of the previously observed 
associations between IPTp and the risk of malaria in 
infants is mediated through prevention of PM.
Methods
Study design, setting, and participants
Data were collected from a birth cohort of infants 
born to HIV-uninfected pregnant women enrolled in a 
randomised controlled trial of monthly IPTp with DP vs 
SP (Trial registration, ClinicalTrials.gov; NCT02793622) 
conducted in Busia district, Uganda, an area of peren-
nial high malaria transmission intensity. Details of the 
study have been previously reported [5, 16, 17]. Pregnant 
women were enrolled at 12-20  weeks of gestation and 
followed through delivery. At delivery, placental blood 
and tissue samples were collected. Following delivery, all 
live births were followed up to 12 months of age. Moth-
ers were encouraged to bring their infants to a dedicated 
study clinic open every day for all their medical care. 
Routine assessments were conducted every 4  weeks for 
clinical assessment and collection of blood smears for the 
detection of parasites by microscopy. Infants presenting 
with a history of fever in the past 24 h or a documented 
tympanic temperature ≥ 38.0 °C had a thick blood smear 
collected for detection of malaria parasites and those 
diagnosed with malaria were treated according to the 
Uganda Ministry of Health guidelines. Non-malarial ill-
nesses were treated according to the integrated manage-
ment of childhood illnesses guidelines. At 12, 28, and 
52  weeks of age, blood was collected for haemoglobin 
measurement.
Laboratory methods
Thick blood smears were stained with 2% Giemsa and 
read by microscopists [5]. Haemoglobin measurements 
were made using a spectrophotometer (Hemocue, 
Angelholm, Sweden). Malaria parasites were detected 
in placental blood by microscopy and loop-mediated 
isothermal amplification (LAMP) [18]. Placental biopsy 
specimens were embedded in paraffin wax, sectioned 
using a rotary microtome, fixed on glass slides, and dehy-
drated in sequential ethanol baths [19]. Separate slides 
were stained in 0.1% haematoxylin and 1% eosin for 5 
and 1 min, respectively, or in 2% Giemsa for 30 min and 
examined for presence of intervillous parasite-infected 
erythrocytes and malaria pigment by two independent 
readers. The proportion of high-power fields (HPF) with 
malaria pigment deposition in fibrin was analysed as 
described [20].
Study outcomes
The primary outcome was the incidence of malaria from 
birth to 12 months of age. An incident episode of malaria 
was defined as the presence of fever (history of fever in 
the past 24 h or a tympanic temperature ≥ 38·0 °C) with 
a positive thick blood smear not preceded by another 
malaria episode in the last 14 days. Secondary outcomes 
included time to first episode of malaria; incidence of 
complicated malaria (malaria with danger signs or meet-
ing standardized criteria for severe malaria), all-cause 
hospitalizations; and non-malarial febrile illnesses; 
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prevalence of malaria parasitaemia during routine vis-
its and anaemia (haemoglobin < 10  g/dL); and infant 
mortality.
Statistical methods
Data were double entered and verified in Microsoft 
Access, and statistical analyses conducted using Stata 
(14.2) including all live births with placental histology 
results. Follow-up began at birth and ended at 12 months 
of age or premature study withdrawal. The primary 
exposure variable, PM, was categorized as follows: no 
PM (absence of parasites or pigment); active PM (para-
sites detected in placental blood or tissue by microscopy 
LAMP or histology, with or without pigment [9, 21]); or 
past PM (presence of pigment, without parasites). Rela-
tionships between past PM and infant malaria incidence 
were initially evaluated by considering the proportion of 
HPF with pigment as a continuous variable. Given the 
non-linear nature of this relationship, past PM was fur-
ther characterized into 2 groups based on best fit asso-
ciations with the outcome variable: mild-moderate past 
PM (> 0–20% HPFs with pigment without parasites); or 
severe past PM (> 20% HPFs with pigment without par-
asites). Analyses were stratified by infant sex a priori. 
Associations between PM and the incidence of malaria 
were performed using negative binomial regression and 
adjusted for maternal parasitaemia status at enrollment, 
IPTp arm, gravidity, housing construction type, and clus-
tering for twin gestation. The cumulative risk of any first 
episode of malaria was compared using a Cox propor-
tional hazards model. For secondary outcomes, incident 
and repeated prevalence measures were compared using 
negative binomial regression model and generalized esti-
mating equations with robust standard errors, respec-
tively. Mediation analysis, using inverse odds weighting 
(IOW) [22], was used to estimate what proportion of 
the reported effect between maternal IPTp regimen and 
malaria incidence in infants [16] was mediated through 
preventing PM (Additional file 1). In brief, three models 
were used to conduct IOW mediation analyses. The first 
model used logistic regression to model treatment given 
mediator (PM) and mediator-outcome confounders. Pre-
dicted probabilities obtained from this model were then 
used to calculate treatment IOWs for each mother-infant 
pair. The second and third models used negative binomial 
regression to model the outcome given treatment with 
and without weights, respectively. The treatment coeffi-
cient from the model with weights estimated the direct 
effect, which was then subtracted from the treatment 
coefficient of the model without weights (total effect) to 
estimate the mediated effect. Bias-corrected 95% con-
fidence intervals (CIs) were computed using bootstrap-
ping. The proportion mediated by PM was calculated 
by dividing the mediated effect by the total effect. In all 
analyses, p-values of < 0·05 were considered statistically 
significant.
Results
Study profile and characteristics of study participants
Between September 2016 and May 2017, 782 HIV-unin-
fected pregnant women were enrolled and randomised 
to receive either IPTp-SP or IPTp-DP, and 687 (87.9%) 
followed through delivery resulting in 678 live births 
(Fig. 1) [16]. A total of 656 infants with placental histol-
ogy results were included in the analyses. Mean mater-
nal age at enrollment was 24  years and 23.5% infants 
were born to primigravida mothers. During pregnancy, 
the incidence of malaria and prevalence of malaria par-
asitaemia were significantly lower among women ran-
domised to IPTp-DP compared to those randomised to 
IPTp-SP. At delivery, women randomised to IPTp-DP 
had a significantly lower prevalence of active PM (2.1% 
versus 21.7% p < 0.001) and severe past PM (1.8% versus 
12.2%, p < 0.001) compared to those randomised to IPTp-
SP (Table 1).
Association between placental malaria and the incidence 
of malaria in infants
Overall, 1088 incident episodes of malaria were diag-
nosed over 596.6 person years of follow-up (1.82 episodes 
per person year). Each 1% increase in the proportion of 
HPF with pigment deposition in fibrin was associated 
with a higher incidence of malaria in infants but the dif-
ference was not statistically significant (adjusted inci-
dence rate ratio [aIRR] 1.98, 95% CI 0.76–5.20, p = 0.16). 
However, on stratifying by infant sex, significant interac-
tion was observed (P-interaction  [pint] = 0.03). Among 
male infants, a 1% increase in HPF with pigment depo-
sition in fibrin was associated with over 5 times higher 
incidence of malaria (aIRR 5.20, 95% CI 1.70–15.94, 
p = 0.004). No significant difference in the incidence of 
malaria was observed in female infants (aIRR 0.53, 95% 
CI 0.13–2.11 p = 0.37). Considering PM as a categorical 
variable, compared to infants born to mothers with no 
PM, the incidence of malaria was higher among infants 
born to mothers with active PM (aIRR 1.30, 95% CI 1.00–
1.71, p = 0.05) and those born to mothers with severe 
past PM (aIRR 1.28, 95% CI 0.89–1.83, p = 0.18, Table 2), 
but the differences were not statistically significant. How-
ever, effect modification by infant sex was also observed 
in the association between categories of PM and the 
incidence of malaria in infants  (pint = 0.02). Compared 
to no PM, severe past PM was associated with a higher 
incidence of malaria among male infants (aIRR 2.17, 95% 
CI 1.45–3.25, p < 0.001), but not among female infants 
(Table 2) .There were no significant associations between 
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active PM or mild-moderate past PM and the incidence 
of malaria in male or female infants. There was no signifi-
cant difference in the overall rate of first malaria episode 
among infants born to mothers with active PM (adjusted 
hazard ratio [aHR] 1.03, 95% CI 0.72–1.47, p = 0.88), 
mild-moderate past PM (aHR 0.92, 95% CI 0.71–1.18, 
p = 0.51), or severe past PM (aHR 1.18, 95% CI 0.75–1.86, 
p = 0.47), compared to those born to mothers with no 
Fig. 1 Study profile. IPTp intermittent preventive treatment in pregnancy, DP dihydroartemisinin–piperaquine, SP sulfadoxine–pyrimethamine
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PM. However, the association between PM and the rate 
of first malaria episode was also modified by infant sex. 
Compared to no PM, severe past PM was associated with 
a significantly higher rate of first malaria episode among 
male infants (aHR 1.99, 95% CI 1.04–3.81, p = 0.04; 
Fig. 2); no significant association was observed in female 
infants.
Association between placental malaria and other malaria 
outcomes in infants
The incidence of complicated malaria was non-sig-
nificantly higher among infants born to mothers with 
active PM (aIRR 1.72, 95% CI 0.81–3.66, p = 0.16), and 
severe past PM (aIRR 2.44, 95% CI 0.93–6.37, p = 0.07; 
Table 3). The prevalence of parasitaemia detected dur-
ing routine visits was also similar among infants born 
to mothers with active or past PM compared to infants 
born to mothers with no PM (Table 3). However, effect 
modification by infant sex was also observed in the 
association between PM and other malaria outcomes. 
Among male infants, severe past PM was associated 
with a nearly four-fold higher incidence of complicated 
malaria (aIRR 3.88, 95% CI 1.14–13.03, p = 0.03) and a 
more than two-fold higher prevalence of malaria para-
sitaemia during routine visits (risk ratio 2.24, 95% CI 
1.34–3.74, p = 0.002) compared to no PM. No signifi-
cant associations were observed among female infants 
(Table 3).
Table 1 Characteristics of study participants
SP Sulfadoxine–pyrimethamine, DP dihydroartemisinin–piperaquine, SD standard deviation, ppy per person year, qPCR quantitative polymerase chain reaction
a Defined as number of routine positive blood smears divided by total number of routine blood smears
No PM no parasites or pigment detected, active PM parasites detected with or without pigment, Past PM (Mild-moderate)  > 0–20% of high-power fields with pigment 
but no parasites, Past PM (severe) > 20%–60% of high-power fields with pigment but no parasites
Characteristic Maternal IPTp arm
Monthly SP (N = 327) Monthly DP (N = 329)
Maternal characteristics at enrolment
 Age in years, mean (SD) 24.0 (5.9) 24.0 (5.7)
 Gravidity, n (%)
  Primigravida/secundigravida 152 (46.5%) 156 (47.4%)
  Multigravida 175 (53.5%) 173 (52.6)
 House-hold type, n (%)
  Modern House 77 (23.6%) 71 (21.6%)
  Traditional House 250 (76.5%) 258 (78.4%)
 Parasite prevalence by microscopy or qPCR, n (%)
  No parasites 53 (16.2%) 63 (19.2%)
  Sub-microscopic parasitaemia 111 (33.9%) 88 (26.8%)
  Microscopic parasitaemia 163 (49.9%) 178 (54.1%)
Maternal characteristics during pregnancy
 Parasite prevalence by microscopy, n/N (%)a 797/2212 (36.0%) 355/2260 (15.7%)
 Incidence of malaria (episodes/ppy) 0.59 0.09
Placental malaria status
 Placental malaria status, n (%)
  No PM 119 (36.4%) 232 (70.5%)
  Active PM 71 (21.7%) 7 (2.1%)
  Past PM (Mild-moderate pigment) 97 (29.7%) 84 (25.5%)
  Past PM (Severe pigment) 40 (12.2%) 6 (1.8%)
  Characteristics of infants at birth
  Preterm birth, n (%) 25 (7.7%) 17 (5.2%)
  Gestation age in weeks, mean (SD) 39.4 (1.9) 39.6 (1.6)
  Low birth weight, n (%) 33 (10.1%) 25 (7.6%)
  Birth weight in grams, mean (SD) 3055 (505) 3024 (409)
  Female sex, n (%) 161 (49.2%) 175 (53.2%)
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Association between placental malaria and non‑malarial 
outcomes in infancy
There were 16 deaths (2.4% of infants) and 25 all-cause 
hospitalisations during follow-up. Severe past PM was 
associated with a non-significant higher incidence of 
all-cause hospitalisations among infants (aIRR 2.90, 95% 
CI 0.59–14.44, p = 0.19; Table  4) compared to no PM. 
There were no significant differences in the incidence of 
non-malaria febrile illnesses and prevalence of anaemia 
during routine visits among infants born to mothers in 
different PM categories compared to no PM (Table 4).
Does prevention of PM explain the difference in infant 
malaria incidence between IPTp‑DP and IPTp‑SP?
Male infants born to mothers who received IPTp-DP 
have been previously reported to have a lower incidence 
of malaria in infancy compared to male infants whose 
mothers received IPTp-SP [16]. Consistent with this prior 
analysis, male infants with placental histology results 
born to mothers who received IPTp-DP had 23% less 
malaria than male infants born to mothers who received 
IPTp-SP (IRR 0.77, 95% CI 0.61–0.99, p = 0.049), but this 
association was not observed in female infants (Table 5). 
Mediation analysis showed that among all infants, 43% 
of IPTp-DP’s greater effect on preventing malaria during 
infancy than IPTp-SP was attributed to preventing PM 
 (IRRmediated 0.95, versus  IRRtotal 0.89, Table  5). In males, 
this proportion was 89.7%  (IRRmediated 0.79 versus  IRRtotal 
0.77). Among female infants, the proportion of mediated 
effect was not calculated because the direct and mediated 
effects were in opposing directions.
Discussion
In this secondary analysis of data from a birth cohort of 
infants born to women randomised to receive monthly 
IPTp with SP vs DP, infants born to mothers with active 
PM and severe past PM had a non-significant higher 
incidence of malaria and complicated malaria during 
the first year of life compared to infants born to moth-
ers without PM. However, the association between severe 
past PM and infant malaria was sex-specific. In male, but 
not female, infants, severe past PM was associated with a 
significantly higher incidence of malaria, a higher rate of 
first malaria episode, a higher incidence of complicated 
malaria, and a higher prevalence of parasitaemia during 
routine visits, compared to no PM. No sex-specific dif-
ferences were observed between active PM and the inci-
dence of malaria in infancy. Importantly, male infants 
born to mothers given IPTp-DP had significantly less 
malaria in infancy than males born to mothers given 
IPTp-SP, and 89.7% of this effect was mediated through 
prevention of PM.
Several prior studies have reported associations 
between active PM defined as detection of parasites 
in placental blood or tissue and an increased risk of 
malaria during infancy [9–11, 23–25]. Active PM 
detected by microscopy was associated with a higher 
risk of malaria infection in Ugandan infants [23], an 
increased rate of first parasitaemia in Beninese infants 
Table 2 Association between different measures of placental malaria and incidence of malaria during infancy
CI confidence interval, IRR incidence rate ratio, mild-mod mild-moderate, PM placental malaria
a Episodes of malaria per person year of follow-up
b Adjusted for gravidity, maternal IPTp, maternal parasitaemia at enrolment, and household type
No PM no parasites or pigment detected, active PM parasites detected with or without pigment, past PM (mild-mod) > 0–20% of high-power fields with pigment but no 
parasites, past PM(severe) > 20%–60% of high-power fields with pigment but no parasites









IRR (95% CI) p value IRR (95% CI) p‑value
All No PM (351) 574 327.4 1.75 Reference group Reference group
Active PM (78) 152 68.9 2.21 1.27 (0.99–1.62) 0.06 1.30 (1.00-1.71) 0.05
Past PM (mild-mod) (181) 271 157.8 1.72 0.97 (0.79–1.18) 0.74 0.94 (0.76-1.16) 0.55
Past PM (severe) (46) 91 42.5 2.14 1.22 (0.91–1.63) 0.19 1.28 (0.89-1.83) 0.18
Male No PM (168) 255 154.5 1.65 Reference group Reference group
Active PM (45) 86 39.9 2.16 1.31 (0.93–1.87) 0.13 1.27 (0.87–1.84) 0.22
Past PM (mild-mod) (70) 129 77.7 1.66 0.98 (0.72–1.35) 0.92 1.02 (0.76–1.36) 0.90
Past PM (severe) (17) 49 15.3 3.20 1.87 (1.29–2.71) 0.001 2.17 (1.45–3.25) <0.001
Female No PM (183) 319 172.9 1.84 Reference group Reference group
Active PM (33) 66 29.0 2.28 1.24 (0.89–1.73) 0.21 1.29 (0.87–1.91) 0.21
Past PM (mild-mod) (91) 142 80.1 1.77 0.96 (0.73–1.24) 0.74 0.81 (0.61–1.08) 0.15
Past PM (severe) (29) 42 27.1 1.55 0.85 (0.58–1.24) 0.40 0.74 (0.46–1.20) 0.22
Page 7 of 11Kakuru et al. Malar J          (2020) 19:449  
[11], and a higher risk of first episode of malaria in 
Gabonese infants [24]. In Mozambique, active PM 
detected by histology was also associated with higher 
odds of malaria compared to no PM [9]. The results 
from the current study, although not statistically sig-
nificant, are consistent with these prior studies. The 
exact mechanisms through which PM might impact on 
the incidence of malaria in infancy are not well under-
stood, but may be due to the effects of PM on the fetal 
immune system, including modulation of innate and 
adaptive cellular immune responses, as well as altered 
maternal–fetal transfer of antibodies to P. falciparum 
[26]. Alternatively, these associations may represent 
confounding secondary to shared levels of exposure to 
malaria parasites between mothers and their infants. To 
limit the effect of confounding by malaria exposure in 
the current study, IPTp arm and markers of exposure, 
including housing structure and maternal parasitaemia 
at enrolment were adjusted for, but the possibility of 
residual confounding persists.
Importantly, in this study, there was an association 
between the severity of past PM, defined as the pro-
portion of HPF with malaria pigment deposition, with 
malaria risk, but only in male infants. Severity of malaria 
pigment deposition in the placenta has been previously 
reported as a strong predictor of adverse birth outcomes 
[15]. To our knowledge, this is the first report to suggest 
that severity of past PM is also associated with increased 
risk of malaria in infancy, and that infant sex may mod-
ify these associations. Although the precise mechanism 
by which infant sex modifies the relationship between 
PM and infant malaria risk remains uncertain, there is 
a growing body of evidence of sex-based differences in 
susceptibility to infectious diseases in infants [27, 28]. 
While one study in southern Sudan suggested that preg-
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Fig. 2 Time to first episode of malaria stratified by infant sex. a All infants, b male infants c  female infants. PM placental malaria, 
mild-mod  mild-moderate, No PM no parasites or pigment detected, active PM parasites detected with or without pigment, past PM 
(mild-mod) > 0–20% of high-power fields with pigment but no parasites, past PM(severe)  > 20%–60% of high-power fields with pigment but no 
parasites
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have PM than those who bore male infants [29], several 
adverse pregnancy outcomes, including stillbirths, have 
been shown to be more common in males than in females 
[30]. This suggests that in utero fetal exposures may 
have more severe consequences for male infants than 
female infants [31]. Furthermore, male infants exposed 
to malaria in utero have been shown to have higher fre-
quencies of regulatory T cells in cord blood compared to 
female infants with similar exposure [32], suggesting that 
in utero malaria exposure may differentially induce toler-
ance to malaria antigens in male, but not female, infants. 
Alternatively, other sex-based differences, including 
malaria-induced responses to toll-like receptor ligands 
[27, 32], expression of x-chromosome encoded genes 
[33], and/or glucocorticoid receptor expression [34] 
may be responsible for these findings. Future studies are 
needed to better understand how PM may result in dif-
ferent sex-specific outcomes in infants.
IPTp with highly effective drugs such as DP can reduce 
the severity of PM, and in this study, IPTp-DP was asso-
ciated with a statistically significant lower incidence of 
malaria among male infants, and a non-significant lower 
incidence of malaria among all infants, compared with 
IPTp-SP. In the mediation analysis, 89.7% of the effect 
Table 3 Association between placental malaria and other malaria outcomes during infancy
CI confidence interval, IRR incidence rate ratio, mild-mod mild-moderate, PM placental malaria, PPY per person year
a Adjusted for gravidity, maternal IPTp, maternal parasitaemia at enrolment, and household type
No PM no parasites or pigment detected, active PM parasites detected with or without pigment, past PM (mild-mod) = > 0–20% of high-power fields with pigment but 
no parasites; past PM(severe) = > 20%–60% of high-power fields with pigment but no parasites





IRR (95% CI) p‑value IRR (95% CI) p‑value
Incidence of compli-
cated malaria
All No PM (351) 30 (0.092) Reference group Reference group
Active PM (78) 12 (0.17) 1.89 (0.93–3.87) 0.08 1.72 (0.81–3.66) 0.16
Past PM (mild-mod) 
(181)
14 (0.09) 0.97 (0.52–1.81) 0.91 0.99 (0.52–1.92) 0.98
Past PM (severe) (46) 9 (0.21) 2.30 (0.97–5.43) 0.06 2.44 (0.93–6.37) 0.07
Male No PM (168) 13 (0.08) Reference group Reference group
Active PM (45) 6 (0.04) 1.78 (0.63–5.02) 0.27 1.18 (0.39–3.62) 0.77
Past PM (mild-mod) 
(90)
11 (0.14) 1.68 (0.76–3.68) 0.20 1.54 (0.44–3.45) 0.30
Past PM (severe) (17) 6 (0.39) 4.61 (1.50–14.22) 0.008 3.88 (1.14–13.03) 0.03
Female No PM (183) 17 (0.10) Reference group Reference group
Active PM (33) 6 (0.21) 2.09 (0.78–5.64) 0.15 2.60 (0.91–7.44) 0.14
Past PM (mild-mod) 
(91)
3 (0.04) 0.38 (0.11–1.29) 0.12 0.44 (0.13–1.54) 0.20
Past PM (severe) (29) 3 (0.11) 1.12 (0.34–3.66) 0.85 1.63 (0.46–5.81) 0.45
Prevalence 
measures
Infant category Placental malaria 
categories
Prevalence n/N (%) Risk ratio (95% CI) p‑value Risk ratio (95% CI) p‑value
Prevalence of prasi-
taemia
All No PM (351) 377/4170 (9.0%) Reference group Reference group
Active PM (78) 82/858 (9.6%) 1.07 (0.76–1.52) 0.70 1.19 (0.82–1.73) 0.36
Past PM (mild-mod) 
(181)
154/1993 (7.7%) 0.85 (0.65–1.12) 0.26 0.86 (0.65–1.14) 0.28
Past PM (severe) (46) 61/542 (11.3%) 1.22 (0.84–1.77) 0.30 1.38 (0.90–2.10) 0.14
Male No PM (168) 170/1964 (8.7%) Reference group Reference group
Active PM (45) 50/498 (10.0%) 1.17 (0.73–1.86) 0.52 1.19 (0.71–2.00) 0.51
Past PM (mild-mod) 
(90)
70/976 (7.2%) 0.81 (0.55–1.20) 0.29 0.87 (0.58–1.31) 0.50
Past PM (severe) (17) 31/191 (16.2%) 1.80 (1.08–2.99) 0.02 2.24 (1.34–3.74) 0.002
Female No PM (183) 207/2206 (9.4%) Reference group Reference group
Active PM (33) 32/360 (8.9%) 0.97 (0.57–1.66) 0.91 1.05 (0.61–1.83) 0.85
Past PM (mild-mod) 
(91)
84/1017 (8.3%) 0.90 (0.61–1.31) 0.57 0.79 (0.53–1.17) 0.24
Past PM (severe) (29) 31/351 (8.6%) 0.90 (0.54–1.51) 0.70 0.86 (0.48–1.52) 0.60
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of IPTp-DP vs SP on the incidence of malaria among 
male infants was mediated through prevention of PM. 
Although this result was not statistically significant, pos-
sibly due to limited sample size to conduct this stratified 
mediation analysis, these results suggest that in addition 
to preventing adverse birth outcomes in all infants, effec-
tive interventions in pregnancy that reduce severe PM 
may also result in a lower risk of malaria in male infants.
In this study, there was no significant association 
between PM and the incidence of non-malaria febrile 
illnesses in infancy, contrary to other reports that sug-
gest that in utero exposure may also influence immune 
responses to non-malarial infections [7, 35]. Further-
more, effective prevention of PM with IPTp-DP was not 
associated with a lower incidence of non-malarial febrile 
illnesses in infancy compared with IPTp-SP [16]. These 
data suggest that PM may specifically impact infant 
malaria risk, although the possibility that it may impact 
other non-malaria infections cannot be excluded.
This study had some limitations. This secondary analy-
sis was exploratory in nature and did not use categories 
of PM based on malaria pigment deposition in fibrin 
used by previous studies [15, 20]. However, prior stud-
ies assessed associations between the severity of pla-
cental pigment and adverse birth outcomes. This is the 
first study to assess associations between the severity of 
placental pigment deposition and infant malaria risk. It 
would be desirable to come up with a standardized classi-
fication system relating the severity of placental pigment 
deposition to infant malaria risk using data from multi-
ple independent studies from different epidemiological 
settings. There were relatively small number of infants in 
the severe past and active PM categories, and these find-
ings should, therefore, be interpreted with caution. The 
Table 4 Association between placental malaria and non-malaria outcomes in infants during the first year of life
CI confidence interval, IRR incidence rate ratio, mild-mod mild-moderate, PM placental malaria
a Adjusted for gravidity, maternal IPTp, maternal parasitaemia at enrolment, and household type
b  Defined as haemoglobin < 10 g/dL measured routinely at 12, 28, and 52 weeks of age
No PM no parasites or pigment detected, active PM parasites detected with or without pigment, past PM (mild-mod) > 0–20% of high-power fields with pigment but no 
parasites, past PM (severe) > 20%–60% of high-power fields with pigment but no parasites





IRR (95% CI) p‑value IRR (95% CI) p‑value
Incidence of all-cause hospi-
talisations
No PM (351) 9 (0.027) Reference group Reference group
Active PM (78) 3 (0.044) 1.66 (0.40–7.00) 0.49 1.14 (0.22–5.98) 0.87
Past PM (mild-mod) (181) 7 (0.044) 1.72 (0.58–5.12) 0.33 1.26 (0.44–3.64) 0.66
Past PM (severe (46) 6 (0.141) 4.85 (1.38–17.00) 0.01 2.90 (0.59–14.44) 0.19
Incidence of non-malarial 
febrile illnesses
No PM (351) 1128 (3.45) Reference group Reference group
Active PM (78) 203 (2.95) 0.86 (0.72–1.03) 0.10 0.84 (0.64–1.10) 0.20
Past PM (mild-mod) (181) 536 (3.40) 0.98 (0.86–1.13) 0.82 1.03 (0.84–1.25) 0.79
Past PM (severe (46) 152 (3.58) 1.04 (0.85–1.26) 0.72 1.06 (0.72–1.57) 0.76
Prevalence measures Categories Prevalence n/N (%) Risk ratio (95% CI) p‑value Risk ratio (95% CI) p‑value
Anaemiac No PM (351) 227/934 (24.3%) Reference group Reference group
Active PM (78) 48/190 (25.3%) 1.07 (0.76–1.50) 0.69 1.00 (0.69–1.47) 0.98
Past PM (mild-mod) (181) 106/441 (24.0%) 1.01 (0.80–1.29) 0.92 0.94 (0.73–1.22) 0.64
Past PM (severe (46) 37/118 (31.4%) 1.29 (0.94–1.77) 0.12 1.16 (0.79–1.70) 0.44
Table 5 Effect of IPTp on malaria incidence in infants that is mediated by preventing placental malaria
CI confidence intervals, IRR incidence rate ratio
IRRs represent the effect of IPTp DP versus SP on the incidence of malaria in infants. Confidence intervals reported here were obtained by bootstrapping and may 
differ from those reported in the primary analysis which used the delta method specifying robust standard errors
a Proportion of mediated effect was calculated using [ln(IRRmediated effect)/ln(IRRtotal effect)]*100
Infant category Total effect Direct effect Mediated effect % 
of mediated 
 effectaIRR (95% CI) p‑value IRR (95% CI) p‑value IRR (95% CI) p‑value
All sexes 0.89 (0.75–1.04) 0.16 0.94 (0.73–1.17) 0.58 0.95 (0.77–1.16) 0.61 43.5%
Male 0.77 (0.61–0.99) 0.05 0.97 (0.67–1.36) 0.89 0.79 (0.56–1.09) 0.17 89.7%
Females 1.01 (0.81–1.26) 0.96 0.92 (0.71–1.22) 0.56 1.09 (0.87–1.38) 0.45 –
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study was conducted in a very high malaria transmission 
setting and therefore its findings cannot be generalized 
to other malaria transmission settings. Finally, exclusion 
of infants with missing placental histology results (3.2%) 
and losses to follow-up may have reduced the power of 
the study and introduced bias if the infants excluded and 
those lost to follow-up were different from those who 
completed follow-up. However, there were no significant 
differences between infants excluded from the analysis, 
those lost to follow-up, and the infants who completed 
the study.
Conclusions
Overall, this study suggests that severe malaria pig-
ment deposition in placental tissue is associated with 
a higher incidence of malaria during the first year of 
life among infants residing in a setting of high malaria 
transmission intensity; however, this association was 
seen in only male infants. Highly effective interventions 
which reduce both severe past and active PM could be 
protective in male infants. Future research is needed 
to evaluate the association between PM and the risk of 
malaria in infancy in larger studies conducted in mod-
erate and high malaria transmission settings and to 
evaluate mechanistic pathways between PM and infant 
malaria risk.
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